Stressgen begins Phase II

Stressgen (TSE:SSB) began a double-blind, placebo-controlled, U.S Phase II study in 52 patients of HspE7 fusion protein of heat shock protein (Hsp) 65 and E7 human papillomavirus (HPV) antigen to trea...